Stereotaxis Earnings Call: High Potential, Tight Runway

Stereotaxis ((STXS)) has held its Q1 earnings call. Read on for the main highlights of the call.

Stereotaxis’ latest earnings call mixed clear strategic momentum with stubborn near‑term financial strain. Management highlighted a wave of regulatory wins, early commercial traction in high‑margin disposables, and a robotics‑led long‑term vision, while acknowledging falling quarterly revenue, higher cash burn, and execution risks that could test investor patience over the next several quarters.

Regulatory Wins Expand the Robotic Ecosystem

Stereotaxis underscored a string of recent approvals, including four U.S. FDA green lights for MAGIC and Synchrony, plus clearances in Europe and China. Together with earlier clearance for Genesys X, these authorizations form a broader product ecosystem that management believes significantly enlarges the company’s procedural and geographic opportunity.

MAGIC Catheter Launch Shows Strong Early Demand

The newly approved MAGIC ablation catheter has already been used at multiple U.S. hospitals, including in complex cases where manual catheters had failed. Physicians reported successful outcomes, and demand is currently running ahead of supply, positioning MAGIC as a potential growth engine if manufacturing can keep pace.

High-Value Disposable Revenue Opportunity Emerges

Initial MAGIC procedures are generating attractive disposable economics, with revenue per case consistently above $5,000 and often above $8,000. Management cited a European hospital ordering roughly $100,000 of disposables for about a month of procedures, and expects year‑end capacity of roughly 500 catheters per month to materially surpass today’s recurring revenue base.

New Digital and Capital Platforms Begin to Commercialize

The company announced FDA clearance and initial orders for Synchrony, a digital surgery cockpit expected to contribute around $3 million of revenue in 2026. In parallel, the Genesys X robotic system, which can be installed without extensive cath lab construction, is building a pipeline as Stereotaxis aims to establish at least five active Genesis programs this year.

Robocath Deal Bolsters Long-Term Robotics Strategy

Stereotaxis highlighted its agreement to acquire Robocath as a strategic step toward broader vascular robotics. By adding a complementary endovascular navigation platform, management believes it can advance a vision of remote, automated robotic care for stroke and cardiovascular disease, potentially expanding use cases well beyond today’s electrophysiology focus.

Guidance Emphasizes 2026 Ramp and MAGIC Scale-Up

Management reaffirmed expectations for double‑digit revenue growth in 2026, targeting more than $40 million in annual sales and forecasting that both the third and fourth quarters will exceed $10 million each. The outlook depends heavily on scaling MAGIC production to roughly 500 catheters per month, delivering at least $3 million from Synchrony, and growing high‑margin disposable revenue per procedure.

Margins Stable as Operating Costs Stay Disciplined

Despite the revenue decline, Stereotaxis reported a 60% gross margin, with recurring revenue margins at 66% and system margins at 39%. Adjusted operating expenses were held essentially flat year over year at $6.7 million, signaling cost discipline as the company funds its product transition and commercial ramp.

Balance Sheet: Cash Cushion but Tight Runway

At quarter‑end the company held $14.6 million in cash and equivalents with no debt outstanding, aided by opportunistic use of an at‑the‑market equity program. Management characterized the balance sheet as sufficient to integrate Robocath and support the ramp, while acknowledging a delicate balancing act and exploring nondilutive, non‑debt financing avenues.

Revenue Contraction Highlights Transitional Pressure

Quarterly revenue fell to $6.3 million from $7.5 million a year earlier, a roughly 16% drop that reflected softness in both systems and recurring sales. System revenue slid 35% to $1.3 million, while recurring revenue declined about 9% to $5.0 million, underscoring the financial drag from legacy products as new offerings ramp.

Johnson & Johnson Exit Weighs on Near-Term Results

The wind‑down of Stereotaxis’ historical catheter relationship with Johnson & Johnson created what management called a messy transition. Supply issues from the outgoing partner constrained procedure volumes and recurring revenue, temporarily masking the underlying growth trajectory of MAGIC and other new disposables in reported results.

Manufacturing Bottlenecks Limit MAGIC Revenue Recognition

The company faced capacity constraints in MAGIC production during the quarter, as process changes early in the year reduced output and pushed much of March manufacturing into April revenue. With demand currently exceeding supply, management stressed that hitting its 500‑catheters‑per‑month goal is critical for both adoption and revenue acceleration.

Losses Deepen and Cash Burn Accelerates

Operating loss for the quarter was $6.0 million, slightly worse than the prior year, with net loss at $5.9 million and adjusted operating loss at $2.9 million. Free cash flow was a negative $3.5 million, almost double the prior year’s cash burn, highlighting that the business remains in investment mode as it builds inventory and scales new platforms.

Weak System Sales and Adoption Risk in Capital Equipment

System sales were particularly soft, totaling only $1.3 million as hospitals navigated the transition to Genesys X and nonintegrated X‑ray compatibility. Management sees a pipeline and backlog, but acknowledges that early pioneering customers must validate workflow and integration, introducing execution risk alongside the more promising disposable ramp.

Outlook Hinges on Execution of Ambitious 2026 Targets

Looking ahead, Stereotaxis’ guidance centers on sequential quarterly growth leading to more than $40 million in 2026 revenue and declining operating losses as recurring revenue scales. Achieving that vision will require timely MAGIC manufacturing expansion, successful commercialization of Synchrony and Genesys X, and careful balance sheet management during a capital‑intensive transition period.

Stereotaxis’ earnings call painted the picture of a company in the midst of a high‑stakes transformation, with breakthrough approvals and early disposable traction offset by falling revenue, tighter liquidity, and operational bottlenecks. For investors, the story now hinges less on technology validation and more on execution, as management works to convert a promising pipeline into sustainable growth and improving profitability.